Tolvaptan for Autosomal Dominant Polycystic Kidney Disease: Pharmacokinetics and Implications for Practice

Type: Article

Authors:

• Cheryl B. Hines, EdD, MSN, CRNA
• Gwendolyn L. Hooper, PhD, APRN-BC, FNP, CUNP
• Angela Collins-Yoder, PhD, RN, CCNS, ACNS, BC, SCRN

Tags: infection end stage renal disease renal stones tolvaptan vasopressin-2 receptor antagonist autosomal dominant polycystic kidney disease kidney cysts renal capsule